As pharmacologic presbyopia therapies become increasingly available, clinicians face important questions regarding patient selection, practice integration, safety considerations, and long-term management strategies. This course will provide a practical framework for incorporating presbyopia drops into everyday optometric care while aligning treatment recommendations with patient lifestyle goals and practice workflows.

Attendees will review how to introduce pharmacologic options during the patient journey, set realistic expectations regarding visual outcomes, and position these therapies as complementary tools alongside glasses and contact lenses. The program will also address key safety considerations, including retinal detachment concerns in higher myopes, mechanism-based differences among available agents, and practical management of side effects such as hyperemia and night vision disturbances.

Real-world patient case including contact lens wearers, high myopes, and post-surgical patient will highlight clinical decision-making strategies and demonstrate how pharmacologic presbyopia therapies can support a comprehensive, individualized approach to vision optimization.

This program is supported in part by an independent medical educational grant from Mylan Inc., a Viatris Company.

Speaker: Milton Hom, O.D., F.A.A.O., F.A.C.A.A.I.(Sc)

Date: Tuesday, October 20, 2026

Time: 5:30 PM - 6:30 PM Pacific Time

Location: Virtual

Moderator: Pending

Cost: Free!

COPE ID: Pending

Category: Pending

This event is undergoing COPE approval for 1 hour CE credit.